Evotec company profile

EVT · Xetra · EUR

Compare Evotec
€2.51Change from previous close: −8.21%Absolute change: −€0.22

Close · November 20, 2026

Company profile

Evotec has 4,379 employees and is headquartered in Hamburg, Germany.

With revenue of EUR 788.4 million in the fiscal year ended December 2025, down 1.1% from the previous year, and a net loss of EUR 103.5 million, Evotec SE employed 4,379 people. The company is headquartered in Hamburg, Germany, was founded in 1993, and changed its name from Evotec AG in April 2019.

Evotec SE focuses on drug discovery and development across oncology, autoimmune and inflammatory disorders, diabetes, heart failure, kidney and liver diseases, rare diseases, and central nervous system and cardiometabolic conditions. Its activity runs through two segments, Shared R&D and Just Evotec Biologics. Its clients range from drugmakers and biotech firms to universities, patient organisations and venture investors. Its markets include the US, Germany, France, Britain, Switzerland and other countries, and it works with academic partners such as the University of Oxford and Johns Hopkins University, as well as with Almirall on severe skin diseases.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Country
Germany
Headquarters
Essener Bogen 7, 22419, Hamburg
Employees
4,379
Chief executive
Christian Wojczewski
Founded
1993
Fiscal year
January - December
Listing
EVT · Xetra
Currency
EUR
ISIN
DE0005664809
Website
evotec.com

Evotec and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
EvotecEVTGermany$489.39M4,379-18.0%—
PharmaNutraPHNItaly$917.61M14622.0%36.7
Faes FarmaFAESpain$1.65B2,67713.0%17.9
FagronFAGRBelgium$1.97B4,88014.3%19.5
AlmirallALMSpain$2.45B2,1089.6%30.2
Siegfried HoldingSFZNSwitzerland$3.4B4,45416.7%16.7

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Evotec with its competitors